P016: DOES LOCAL WOUND INFILTRATION WITH LIPOSOMAL BUPIVACAINE (EXPAREL®) REDUCE NARCOTIC REQUIREMENTS OR LENGTH-OF-STAY AFTER BARIATRIC OPERATIONS?
Patrick Ziemann-Gimmel, MD1, Robert Marema, MD2, Allison A Goldfarb, ARNP, DNP, CRNA1, Meghan Connelly, CRNA1; 1Sheridan, 2US Bariatrics
Introduction: Liposomal bupivacaine (LB) is FDA approved for ankle block and local infiltration after hemorrhoid surgery. It has found widespread use in local infiltration in orthopedic and general surgery. Our institution started using it approximately 10 months ago. The purpose of this study is to compare the narcotic use and length-of-stay after bariatric surgery before (control) and after the introduction of LB into our clinical practice. The hypothesis is that the use of LB reduces narcotic requirements and length of stay compared to the use of “regular” bupivacaine.
Methods: The data was collected as part of a prospective randomized trial investigating residual weakness (clinicaltrials.gov NCT02037516) from 01/01/2014 to 01/31/2016. Starting in 03/01/2015 LB was used. The data will be analyzed using standard statistical methods. Data will be analyzed using standard statistical test to determine the comparability of both groups, LOS and in opioid consumption. Pain scores will not be analyzed due to the bias towards the inferior group. (Pain scores are recorded once per shift and when a patient requires pain medication.) Secondary outcomes will be the analysis of antiemetic rescue medication.
Results: Data from approximately 320 patients (160 control and 160 study) have been collected and will be analyzed and baseline characteristics, surgical procedure, narcotic consumption and length of stay.